Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma

Over the past 30 years, there has been no significant improvement in treatment outcomes for patients with advanced stage IV metastatic melanoma, and prognosis remains poor. Melanoma is known to be responsive to immunomodulatory agents, to be a highly vascular tumor, and to be fairly resistant to sta...

Full description

Bibliographic Details
Main Authors: Wen-Jen Hwu, Ana E. Ayala, Ingrid M. Hernandez
Format: Article
Language:English
Published: PAGEPress Publications 2011-12-01
Series:Oncology Reviews
Subjects:
Online Access:http://www.oncologyreviews.org/index.php/or/article/view/125